Table 2.
Clinical characterization of the study cohort.
| Factor | Total | Alive* | Deceased* |
|---|---|---|---|
| N | 14,425 | 9,733 | 4,692 |
| Treatment outcome | |||
| Unchanged | 580 (4.0%) | 580 (6.0%) | 0 (0.0%) |
| Recovery | 3,410 (23.6%) | 3,410 (35.0%) | 0 (0.0%) |
| Transferred to a 24-h hospital | 4 (<1%) | 4 (<1%) | 0 (0.0%) |
| Death | 4,692 (32.5%) | 0 (0.0%) | 4,692 (100.0%) |
| Improvement | 4,401 (30.5%) | 4,401 (45.2%) | 0 (0.0%) |
| Deterioration | 1 (<1%) | 1 (<1%) | 0 (0.0%) |
| Missing | 1,337 (9.3%) | 1,337 (13.7%) | 0 (0.0%) |
| Stage (TNM) | |||
| I | 5,100 (35.4%) | 4,558 (46.8%) | 542 (11.6%) |
| II | 6,085 (42.2%) | 3,546 (36.4%) | 2,539 (54.1%) |
| III | 1,913 (13.3%) | 757 (7.8%) | 1,156 (24.6%) |
| IV | 525 (3.6%) | 98 (1.0%) | 427 (9.1%) |
| missing | 802 (5.6%) | 774 (8.0%) | 28 (0.6%) |
| Stage (FIGO) | |||
| I | 5,248 (36.4%) | 4,668 (48.0%) | 580 (12.4%) |
| II | 6,337 (43.9%) | 3,675 (37.8%) | 2,662 (56.7%) |
| III | 1,597 (11.1%) | 558 (5.7%) | 1,039 (22.1%) |
| IV | 441 (3.1%) | 58 (0.6%) | 383 (8.2%) |
| missing | 802 (5.6%) | 774 (8.0%) | 28 (0.6%) |
| ICD-10 code | |||
| C53 | 1,219 (8.5%) | 990 (10.2%) | 229 (4.9%) |
| C53.0 | 4,961 (34.4%) | 3,501 (36.0%) | 1,460 (31.1%) |
| C53.1 | 3,478 (24.1%) | 2,494 (25.6%) | 984 (21.0%) |
| C53.8 | 3,205 (22.2%) | 1,839 (18.9%) | 1,366 (29.1%) |
| C53.9 | 1,562 (10.8%) | 909 (9.3%) | 653 (13.9%) |
| Hospitalization type | |||
| Planned hospitalization | 10,675 (74.0%) | 7,094 (72.9%) | 3,581 (76.3%) |
| Emergency | 239 (1.7%) | 78 (0.8%) | 161 (3.4%) |
| Missing | 3,511 (24.3%) | 2,561 (26.3%) | 950 (20.2%) |
| Morphological type of tumor | |||
| Adenocarcinoma | 970 (6.7%) | 528 (5.4%) | 442 (9.4%) |
| Squamous cell carcinoma | 10,807 (74.9%) | 7,078 (72.7%) | 3,729 (79.5%) |
| Other | 1,184 (8.2%) | 744 (7.6%) | 440 (9.4%) |
| Missing | 1,464 (10.1%) | 1,383 (14.2%) | 81 (1.7%) |
| Reason for late diagnosis | |||
| Incomplete examination | 29 (0.2%) | 7 (0.1%) | 22 (0.5%) |
| Untimely medical examination | 11 (0.1%) | 1 (<1%) | 10 (0.2%) |
| Untimely referral | 1,295 (9.0%) | 396 (4.1%) | 899 (19.2%) |
| Refusal of examination | 7 (<1%) | 3 (<1%) | 4 (0.1%) |
| Error of other specialists | 13 (0.1%) | 5 (0.1%) | 8 (0.2%) |
| Clinical error | 18 (0.1%) | 5 (0.1%) | 13 (0.3%) |
| Latent course of disease | 328 (2.3%) | 100 (1.0%) | 228 (4.9%) |
| Missing | 12,724 (88.2%) | 9,216 (94.7%) | 3,508 (74.8%) |
| Diagnosis circumstance | |||
| In a female/male examination room | 2,186 (15.2%) | 1,425 (14.6%) | 761 (16.2%) |
| Self-referral | 5,476 (38.0%) | 3,074 (31.6%) | 2,402 (51.2%) |
| Under other circumstances | 640 (4.4%) | 388 (4.0%) | 252 (5.4%) |
| Under other types medical examination | 3,267 (22.6%) | 2,310 (23.7%) | 957 (20.4%) |
| During screening | 1,657 (11.5%) | 1,370 (14.1%) | 287 (6.1%) |
| Missing | 1,199 (8.3%) | 1,166 (12.0%) | 33 (0.7%) |
| Disease status | |||
| Local primary process | 2,720 (18.9%) | 1,485 (15.3%) | 1,235 (26.3%) |
| Metastatic/systemic process | 6,571 (45.6%) | 4,750 (48.8%) | 1,821 (38.8%) |
| New primary tumor | 21 (0.1%) | 14 (0.1%) | 7 (0.1%) |
| Remission/NED | 304 (2.1%) | 91 (0.9%) | 213 (4.5%) |
| Relapse (organ/extra organ) | 58 (0.4%) | 50 (0.5%) | 8 (0.2%) |
*By the time of registry download (11 October 2024).